Immune checkpoint blockades
tumor, ICBs
TUMOR, CERVICAL CANCER
Since the mechanisms of tumor antigen presentation and tumor microenvironment (TME) are explored more deeply, ICBs and their related fields have been a popular topic in the field of cervical cancer. And until now, ICBs also have made significant progress . There are two types of immune checkpoints, co-stimulatory immune checkpoints such as OX40, ICOS, and 4-1BB (CD137), and co-inhibitory immune checkpoints such as PD1, CTLA-4, and LAG-3 (The mechanism of immune checkpoint blockades is relatively simple. Here, take PD-1/PD-L1 as an example. When the inhibitory immune checkpoint PD-1 expressed by some kinds of immune cells such as CD8+ T cells and (or) its corresponding ligand PD-L1 expressed by tumor cells are blocked, the exhaustion of T cells will be impaired, and the immune system will be enhanced (Our study incorporated 221 clinical trials associated with ICBs, and there are multiple treatment patterns for cervical cancer currently.